

Lee S Simon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/322347/publications.pdf>

Version: 2024-02-01

49
papers

4,685
citations

430442

18
h-index

223531

46
g-index

64
all docs

64
docs citations

64
times ranked

5914
citing authors

#	ARTICLE	IF	CITATIONS
1	OMERACT 2020: A virtual (R)evolution. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 588-592.	1.6	0
2	What are the domains and outcome measures used in the existing neuropsychiatric systemic lupus erythematosus literature?. <i>Rheumatology</i> , 2021, 61, 6-7.	0.9	1
3	Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1139-1145.	1.6	8
4	Feasibility and Face Validity of Outcome Measures for Use in Future Studies of Polymyalgia Rheumatica: An OMERACT Study. <i>Journal of Rheumatology</i> , 2020, 47, 1379-1384.	1.0	10
5	Toward a Core Domain Set for Glucocorticoid Impact in Inflammatory Rheumatic Diseases: The OMERACT 2018 Glucocorticoid Impact Working Group. <i>Journal of Rheumatology</i> , 2019, 46, 1179-1182.	1.0	8
6	Toward a Core Outcome Measurement Set for Polymyalgia Rheumatica: Report from the OMERACT 2018 Special Interest Group. <i>Journal of Rheumatology</i> , 2019, 46, 1360-1364.	1.0	5
7	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1028-1035.	1.0	61
8	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1053-1058.	1.0	8
9	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1173-1178.	1.0	6
10	Patient Perspectives on DMARD Safety Concerns in Rheumatology Trials: Results from Inflammatory Arthritis Patient Focus Groups and OMERACT Attendees Discussion. <i>Journal of Rheumatology</i> , 2019, 46, 1168-1172.	1.0	8
11	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. <i>Journal of Rheumatology</i> , 2019, 46, 1021-1027.	1.0	97
12	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1014-1020.	1.0	65
13	A Patient-reported Outcome Measure for Effect of Glucocorticoid Therapy in Adults with Inflammatory Diseases Is Needed: Report from the OMERACT 2016 Special Interest Group. <i>Journal of Rheumatology</i> , 2017, 44, 1754-1758.	1.0	16
14	The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2017, 44, 1515-1521.	1.0	33
15	Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. <i>Journal of Rheumatology</i> , 2017, 44, 1551-1559.	1.0	27
16	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 1916-1919.	1.0	11
17	Development of a Provisional Core Domain Set for Polymyalgia Rheumatica: Report from the OMERACT 12 Polymyalgia Rheumatica Working Group. <i>Journal of Rheumatology</i> , 2016, 43, 182-186.	1.0	25
18	Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain. <i>Journal of Rheumatology</i> , 2015, 42, 1947-1953.	1.0	20

#	ARTICLE	IF	CITATIONS
19	Dialogue on Developing Consensus on Measurement and Presentation of Patient-important Outcomes, Using Pain Outcomes as an Exemplar, in Systematic Reviews: A Preconference Meeting at OMERACT 12. Journal of Rheumatology, 2015, 42, 1931-1933.	1.0	9
20	Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda. Journal of Rheumatology, 2015, 42, 1934-1942.	1.0	7
21	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. Journal of Clinical Epidemiology, 2014, 67, 745-753.	2.4	625
22	A CLINICAL TRIALS MANUAL FROM THE DUKE CLINICAL RESEARCH INSTITUTE: LESSONS FROM A HORSE NAMED JIM. Journal of Pain and Palliative Care Pharmacotherapy, 2011, 25, 76-77.	0.5	0
23	A first step to assess harm and benefit in clinical trials in one scale. Journal of Clinical Epidemiology, 2010, 63, 627-632.	2.4	25
24	How to Ascertain Drug Safety in the Context of Benefit. Controversies and Concerns: Table 1.. Journal of Rheumatology, 2009, 36, 2114-2121.	1.0	7
25	Observations from the OMERACT Drug Safety Summit, May 2008. Journal of Rheumatology, 2009, 36, 2110-2113.	1.0	6
26	Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain, 2009, 143, 238-245.	2.0	171
27	Do topical NSAIDs work?. Nature Clinical Practice Rheumatology, 2008, 4, 458-459.	3.2	3
28	Frequency of COX2-inhibitor use in the clinic prior to market withdrawals. Nature Clinical Practice Rheumatology, 2007, 3, 16-17.	3.2	1
29	Osteoporosis. Rheumatic Disease Clinics of North America, 2007, 33, 149-176.	0.8	17
30	Preliminary development of a responder index for chronic low back pain. Journal of Rheumatology, 2007, 34, 1386-91.	1.0	20
31	The COX 2 selective inhibitors: what the newspapers have not told you. Bulletin of the NYU Hospital for Joint Diseases, 2007, 65, 229-41.	0.7	4
32	Is milnacipran effective in treating pain in patients with fibromyalgia?. Nature Clinical Practice Rheumatology, 2006, 2, 126-127.	3.2	0
33	A food and drug administration primer. Arthritis and Rheumatism, 2006, 55, 4-8.	6.7	1
34	Patient-Reported Pain is Central to OMERACT Rheumatology Core Measurement Sets. Drug Information Journal, 2006, 40, 111-116.	0.5	2
35	Perception of risk: The state of COX-2 selective inhibitors. Current Rheumatology Reports, 2005, 7, 163-166.	2.1	2
36	Osteoporosis. Clinics in Geriatric Medicine, 2005, 21, 603-629.	1.0	31

#	ARTICLE	IF	CITATIONS
37	The COX-2 inhibitors: a reasoned review of the data. <i>Swiss Medical Weekly</i> , 2005, 135, 419-24.	0.8	2
38	A world without Vioxx: to COX-2 or not to COX-2?. <i>Cleveland Clinic Journal of Medicine</i> , 2004, 71, 849-850.	0.6	4
39	Rofecoxib, but not celecoxib or naproxen, increases mean 24-hour systolic blood pressure: results of a randomized double blind controlled trial in treated hypertensive patients with osteoarthritis (OA) and type 2 diabetes mellitus. <i>American Journal of Hypertension</i> , 2003, 16, A11.	1.0	3
40	Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. <i>Arthritis and Rheumatism</i> , 2000, 43, 4-13.	6.7	273
41	Intraarticular injection of hyaluronan as treatment for knee osteoarthritis: What is the evidence?. <i>Arthritis and Rheumatism</i> , 2000, 43, 1192-1203.	6.7	173
42	Osteoarthritis. <i>Current Rheumatology Reports</i> , 1999, 1, 45-47.	2.1	17
43	Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: Efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. <i>Arthritis and Rheumatism</i> , 1998, 41, 1591-1602.	6.7	457
44	Cyclooxygenase in biology and disease. <i>FASEB Journal</i> , 1998, 12, 1063-1073.	0.2	2,208
45	NSAIDs and the Elderly. <i>Drugs and Aging</i> , 1997, 10, 119-130.	1.3	38
46	Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 819-825.	6.7	123
47	Changes in serum levels of type I and III procollagen extension peptides during infusion of human parathyroid hormone fragment (1-34). <i>Journal of Bone and Mineral Research</i> , 1988, 3, 241-246.	3.1	20
48	Knowledge Translation for Patients: Methods to Support Patients' Participation in Decision making about Preference-Sensitive Treatment Options in Rheumatology. , 0, , 41-62.		1
49	OMERACT: An Ongoing Evidence-Based Initiative to Improve the Quality of Outcome Measures in Rheumatology. , 0, , 19-24.		1